Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to -$1.1 million.

  • Agios Pharmaceuticals' Change in Account Payables fell 5145.5% to -$1.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 million, marking a year-over-year decrease of 7354.95%. This contributed to the annual value of $1.7 million for FY2025, which is 7354.95% down from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Change in Account Payables of -$1.1 million as of Q4 2025, which was down 5145.5% from $1.8 million recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Change in Account Payables ranged from a high of $8.1 million in Q4 2022 and a low of -$9.8 million during Q1 2023
  • Over the past 5 years, Agios Pharmaceuticals' median Change in Account Payables value was $337000.0 (recorded in 2024), while the average stood at $245650.0.
  • Its Change in Account Payables has fluctuated over the past 5 years, first soared by 55020.24% in 2021, then tumbled by 29727.27% in 2025.
  • Agios Pharmaceuticals' Change in Account Payables (Quarter) stood at $5.2 million in 2021, then skyrocketed by 55.08% to $8.1 million in 2022, then crashed by 143.8% to -$3.5 million in 2023, then surged by 78.6% to -$756000.0 in 2024, then plummeted by 51.46% to -$1.1 million in 2025.
  • Its Change in Account Payables stands at -$1.1 million for Q4 2025, versus $1.8 million for Q3 2025 and $3.9 million for Q2 2025.